专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1993020816A1 ANGIOTENSIN II ANTAGONISTS AGAINST DISORDERS ASSOCIATED WITH IMPAIRED NEURONAL CONDUCTION VELOCITY, ESPECIALLY DIABETIC NEUROPATHY 审中-公开
标题翻译： ANGIOTENSIN II对抗相关疾病的危险神经导管速度，特别是糖尿病神经病变
公开(公告)号：WO1993020816A1
公开(公告)日：1993-10-28
申请号：PCT/GB1993000732
申请日：1993-04-07
申请人： ZENECA LIMITED , CAREY, Frank , OLDHAM, Alexander, Anthony , CAMERON, Norman, Eugene , COTTER, Mary, Anne
发明人： ZENECA LIMITED
IPC分类号： A61K31/415
CPC分类号： A61K31/4164 , A61K31/415 , A61K31/4375 , A61K31/44 , A61K31/4439 , A61K31/47 , A61K31/4709
摘要： This invention relates to the use of angiotensin II antagonists in treating or preventing the development of disease conditions associated with impaired neuronal conduction velocity, such as diabetic neuropathy, as well as their use in the manufacture of a medicament for use in such treatment. The invention also concerns pharmaceutical compositions containing an angiotensin II antagonist together with one or more other agents known to be of value in treating or preventing the development of disease conditions associated with impaired neuronal conduction velocity.
摘要翻译：本发明涉及血管紧张素II拮抗剂在治疗或预防与神经元传导速度受损有关的疾病状态的发展中的应用，例如糖尿病性神经病，以及它们在制备用于这种治疗的药物中的用途。本发明还涉及含有血管紧张素II拮抗剂以及一种或多种已知在治疗或预防与受损的神经元传导速度相关的疾病状况发展中具有重要价值的其它药物的药物组合物。

2. 发明申请

WO2006025057A8 USE OF IL-6 IN VASCULAR COMPLICATIONS 审中-公开
标题翻译： IL-6在血管收缩中的应用
公开(公告)号：WO2006025057A8
公开(公告)日：2007-05-18
申请号：PCT/IL2005000928
申请日：2005-08-31
申请人： APPLIED RESEARCH SYSTEMS , EINAV HENRY , DREANO MICHEL , VITTE PIERRE-ALAIN , CAMERON NORMAN , COTTER MARY
发明人： DREANO MICHEL , VITTE PIERRE-ALAIN , CAMERON NORMAN , COTTER MARY
IPC分类号： A61K38/20 , A61K20060101 , A61P13/00 , A61P25/02
CPC分类号： A61K38/204
摘要： Abstract The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.
摘要翻译：摘要本发明涉及IL-6或其片段，变体，融合蛋白，功能衍生物或其盐在微血管并发症中的应用。

3. 发明申请

WO2006068988A1 COMBINATION THERAPY FOR VASCULAR COMPLICATIONS ASSOCIATED WITH HYPERGLYCEMIA 审中-公开
标题翻译：与高血压相关的血管充血综合治疗
公开(公告)号：WO2006068988A1
公开(公告)日：2006-06-29
申请号：PCT/US2005/045865
申请日：2005-12-16
申请人： ELI LILLY AND COMPANY , CAMERON, Norman, Eugene , MEST, Hans-Jurgen , SEEDORF, Klaus , SEEDORF, Luitgard
发明人： CAMERON, Norman, Eugene , MEST, Hans-Jurgen , SEEDORF, Klaus , SEEDORF, Luitgard
IPC分类号： A61K31/4015 , A61K31/04 , A61K31/366 , A61P9/10
CPC分类号： A61K31/366 , A61K31/04 , A61K31/4015 , A61K31/404 , A61K2300/00
摘要： The present invention relates to a method of treating one or more vascular complications of hyperglycemia comprising administering to a patient in need of treatment for one or more vascular complications to hyperglycemia a therapeutically effective amount of ruboxistaurin, or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of an HMG-CoA reductase inhibitor.
摘要翻译：本发明涉及一种治疗高血糖症的一种或多种血管并发症的方法，其包括向需要治疗一种或多种血管并发症的患者施用治疗高血糖症的治疗有效量的ruboxistaurin或其药学上可接受的盐与治疗有效量的HMG-CoA还原酶抑制剂。

4. 发明申请

WO2010125330A1 USE OF PUFAS TO TREAT NERVE DAMAGE 审中-公开
标题翻译：使用PUFAS治疗神经损伤
公开(公告)号：WO2010125330A1
公开(公告)日：2010-11-04
申请号：PCT/GB2010/000817
申请日：2010-04-22
申请人： EQUATEQ LIMITED , KELLIHER, Adam , CAMERON, Norman , MORRISON, Angus , KNOWLES, Phil
发明人： KELLIHER, Adam , CAMERON, Norman , MORRISON, Angus , KNOWLES, Phil
IPC分类号： A61K31/202 , A61P25/02 , A61P3/10
CPC分类号： A61K31/202
摘要： The present invention provides use of compounds which are polyunsaturated fatty acid (PUFA) derivatives of formula (I), in the form of racemates, stereoisomers or mixtures of stereoisomers, or pharmaceutically acceptable salts, or solvates thereof, wherein -AIk- is -(CH 2 ) 4 -CH(OR 2 )-[trans]CH=CH-[cis]CH=CH-, -(CH 2 ) 4 -[cis]CH=CH- [trans]CH=CH-CH(OR 2 )-, -CH(OR 2 )-[trans]CH=CH-[cis]CH=CH-CH 2 - [cis]CH=CH-(CH 2 ) 3 -, -(CH 2 ) 3 -CH(OR 2 )-[trans]CH=CH-[cis]CH=CH-CH 2 - [cis]CH=CH-, or -(CH 2 ) 3 -[cis]CH=CH-CH 2 -[cis]CH=CH-[trans]CH=CH- CH(OR 2 )-; R 1 is a hydrogen atom; or R 1 is a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, C 3 -C 7 carbocyclyl or 5- to 10-membered heterocyclyl group; or R 1 is a group of formula -CH 2 -CH(OR 3 )-CH 2 -(OR 4 ), wherein R 3 and R 4 are each independently hydrogen atoms or -(C=O)-R 6 , wherein R 6 is an aliphatic group having from 3 to 29 carbon atoms; or R 1 is a group of formula -(CH 2 OCH 2 ) m OH, wherein m is an integer of from 1 to 200; or R 1 is a drug moiety; each R 2 is the-same or different- and each independently represents a hydrogen atom; or a group -(C=O)-R 5 , wherein R 5 is a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 - C 10 aryl, 5- to 10-membered heteroaryl, C 3 -C 7 carbocyclyl or 5- to 10-membered heterocyclyl group, or R 5 is an aliphatic group having from 3 to 29 carbon atoms, or R 5 is a drug moiety; or a group of formula -(CH 2 OCH 2 ) n OH, wherein n is an integer of from 1 to 200; or a drug moiety; and wherein said alkyl, alkenyl, alkynyl and aliphatic groups are the same or different and are each unsubstituted or substituted with 1, 2 or 3 unsubstituted substituents which are the same or different and are selected from halogen atoms and C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 1 -C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 1 -C 4 haloalkoxy, C 2 -C 4 haloalkenyloxy, hydroxyl, -SR', and -NR'R" groups where R' and R" are the same or different and represent hydrogen or unsubstituted C 1 -C 2 alkyl; said aryl, heteroaryl, carbocyclyl and heterocyclyl groups are the same or different and are each unsubstituted or substituted by 1, 2, 3 or 4 unsubstituted substituents which are the same or different and are selected from halogen atoms, and cyano, nitro, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyl, C 2 -C 4 alkenyloxy, C 1 - C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 1 -C 4 haloalkoxy, C 2 -C 4 haloalkenyloxy, hydroxyl, C 1 -C 4 hydroxyalkyl, -SR' and -NR'R" groups wherein each R' and R" is the same or different and represents hydrogen or unsubstituted C 1 -C 4 alkyl; in the manufacture of a medicament for use in treating or preventing nerve damage in a mammal.
摘要翻译：本发明提供了以外消旋物，立体异构体或立体异构体或其药学上可接受的盐或溶剂化物的形式的式（I）的多不饱和脂肪酸（PUFA）衍生物的化合物的用途，其中-AIk-是 - （（CH 2）4 - [顺式] CH = CH- [反式] CH = CH-CH（OR 2） - ， -CH（OR 2） - [反式] CH = CH- [顺式] CH = CH-CH 2 - [顺式] CH = CH-（CH 2）3 - ， - （CH 2）3 -CH（OR 2） - [反式] = CH- [顺式] CH = CH-CH 2 - [顺式] CH = CH-或 - （CH 2）3 - [顺式] CH = CH-CH 2 - [顺式] CH = CH- [反式] CH = CH（OR2） - ; R1是氢原子; 或R 1是C 1 -C 6烷基，C 2 -C 6烯基，C 2 -C 6炔基，C 6 -C 10芳基，5至10元杂芳基，C 3 -C 7碳环基或5至10元杂环基; 或R 1是式-CH 2 -CH（OR 3）-CH 2 - （OR 4）的基团，其中R 3和R 4各自独立地为氢原子或 - （C = O）-R 6，其中R 6为具有3至 29个碳原子; 或R 1是式 - （CH 2 OCH 2）m OH的基团，其中m是1至200的整数; 或R1是药物部分; 每个R 2相同或不同，并且各自独立地表示氢原子; 或基团 - （C = O）-R 5，其中R 5是C 1 -C 6烷基，C 2 -C 6烯基，C 2 -C 6炔基，C 6 -C 10芳基，5至10元杂芳基，C 3 -C 7碳环基或5 至10元杂环基，或R 5为具有3至29个碳原子的脂族基，或R 5为药物部分; 或式 - （CH 2 OCH 2）n OH的基团，其中n为1至200的整数; 或药物部分; 并且其中所述烷基，烯基，炔基和脂族基团相同或不同，并且各自是未取代的或被1,2或3个相同或不同的未取代的取代基取代，并且选自卤素原子和C 1 -C 4烷氧基， C4链烯氧基，C1-C4卤代烷基，C2-C4卤代烯基，C1-C4卤代烷氧基，C2-C4卤代烯氧基，羟基，-SR'和-NR'R“基团，其中R'和R”相同或不同，表示氢或未取代的C 1 -C 2烷基; 所述芳基，杂芳基，碳环基和杂环基相同或不同，并且各自是未取代的或被1,2,3或4个相同或不同并且选自卤素原子的未取代的取代基取代，氰基，硝基，C1- C 4烷基，C 1 -C 4烷氧基，C 2 -C 4烯基，C 2 -C 4烯氧基，C 1 -C 4卤代烷基，C 2 -C 4卤代烯基，C 1 -C 4卤代烷氧基，C 2 -C 4卤代链烯氧基，羟基，C 1 -C 4羟基烷基， NR'R“基团，其中每个R'和R”相同或不同，表示氢或未取代的C 1 -C 4烷基; 在制备用于治疗或预防哺乳动物神经损伤的药物中。

5. 发明申请

WO2006025057A1 USE OF IL-6 IN VASCULAR COMPLICATIONS 审中-公开
标题翻译： IL-6在血管收缩中的应用
公开(公告)号：WO2006025057A1
公开(公告)日：2006-03-09
申请号：PCT/IL2005/000928
申请日：2005-08-30
申请人： APPLIED RESEARCH SYSTEMS ARS HOLDING N.V , EINAV, Henry , DREANO, Michel , VITTE, Piere-Alain , CAMERON, Norman , COTTER, Mary
发明人： DREANO, Michel , VITTE, Piere-Alain , CAMERON, Norman , COTTER, Mary
IPC分类号： A61K38/20 , A61P25/02 , A61P13/00
CPC分类号： A61K38/204
摘要： Abstract The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.
摘要翻译：摘要本发明涉及IL-6或其片段，变体，融合蛋白，功能衍生物或其盐在微血管并发症中的应用。

6. 发明申请

WO0130331A3 THERAPEUTIC COMPOSITIONS INCLUDING PROTEIN KINASE C INHIBITORS 审中-公开
标题翻译：包括蛋白激酶C抑制剂的治疗组合物
公开(公告)号：WO0130331A3
公开(公告)日：2002-01-24
申请号：PCT/US0026254
申请日：2000-10-13
申请人： LILLY CO ELI , CAMERON NORMAN EUGENE , WAYS DOUGLAS KIRK
发明人： CAMERON NORMAN EUGENE , WAYS DOUGLAS KIRK
IPC分类号： A61K45/06 , A61K31/00 , A61P3/10
CPC分类号： A61K45/06
摘要： Compositions comprising a PKC inhibitor, or a pharmaceutically acceptable salt thereof, and an antioxidant, essential fatty acid, or a prostacyclin agent, or a pharmaceutically acceptable salt thereof are provided. Also provided are methods of treatment comprising administration of such compositions, and methods of treatment comprising co-administration of a PKC inhibitor, or a pharmaceutically acceptable salt thereof, and an antioxidant, essential fatty acid, or a prostacyclin agent, or a pharmaceutically acceptable salt thereof.
摘要翻译：提供了包含PKC抑制剂或其药学上可接受的盐，抗氧化剂，必需脂肪酸或前列环素试剂或其药学上可接受的盐的组合物。还提供了包括施用这样的组合物的治疗方法和包括共同给予PKC抑制剂或其药学上可接受的盐，抗氧化剂，必需脂肪酸或前列环素试剂或其药学上可接受的盐的治疗方法它们。

7. 发明专利

IL181416D0 USE OF IL-6 IN VASCULAR COMPLICATIONS 未知
公开(公告)号：IL181416D0
公开(公告)日：2008-03-20
申请号：IL18141607
申请日：2007-02-19
申请人： DREANO MICHEL , VITTE PIERRE ALAIN , CAMERON NORMAN , COTTER MARY , SERONO LAB , APPLIED RESEARCH SYSTEMS
IPC分类号： A61K20100101 , A61K38/20
摘要： The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.

8. 发明授权

US2171489A Ashtray and cigarette extinguisher 失效
标题翻译：烟灰缸和香烟灭火器
公开(公告)号：US2171489A
公开(公告)日：1939-08-29
申请号：US13990637
申请日：1937-04-30
申请人： CAMERON NORMAN M
发明人： CAMERON NORMAN M
IPC分类号： A24F19/14
CPC分类号： A24F19/14

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式